A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States
Overall, the cell-based vaccine was cost-saving compared to the recombinant vaccine for subjects aged 18-64 years in the US, achieving comparable health outcomes with a significant reduction in associated costs.
Authors
- Neda Al Rawashdh
- Emily B. Kahn (ORCID: https://orcid.org/0000-0001-7812-7958)
- Pablo Anaya (ORCID: https://orcid.org/0000-0002-0953-4952)
- Myron J. Levin (ORCID: https://orcid.org/0000-0002-7468-106X)
- Joaquin Mould-Quevedo (ORCID: https://orcid.org/0000-0003-4847-5956)
- Richard M. Zur (ORCID: https://orcid.org/0000-0002-2040-0146)
- Daniel Yu
- Liliane Mofor
Institutions
- IQVIA (United States) (US)
- Seqirus (United States) (US)
- CSL (Australia) (AU)
- IQ Solutions (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Vaccines
- Published
- 2024-10-26
- DOI
- https://doi.org/10.3390/vaccines12111217
- Citations
- 2
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Moderna
- Seqirus